Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The potential impact of azithromycin in idiopathic pulmonary fibrosis

Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
European Respiratory Journal 2019 53: 1800628; DOI: 10.1183/13993003.00628-2018
Claudio Macaluso
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
3These authors contributed equally to the study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joaquín Maritano Furcada
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
3These authors contributed equally to the study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omamah Alzaher
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ritesh Chaube
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Chua
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athol U. Wells
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toby M. Maher
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. George
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Renzoni
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip L. Molyneaux
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    a) Characteristics of the idiopathic pulmonary fibrosis (IPF) subjects. Comparison of b) courses of antibiotics (p=0.0086) and c) hospital admissions (p<0.0001) before and after the use of azithromycin per patient years. FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.

PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 2 Table of Contents
European Respiratory Journal: 53 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The potential impact of azithromycin in idiopathic pulmonary fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
European Respiratory Journal Feb 2019, 53 (2) 1800628; DOI: 10.1183/13993003.00628-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
European Respiratory Journal Feb 2019, 53 (2) 1800628; DOI: 10.1183/13993003.00628-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Mitochondrial DNA as biomarker of survival in RA-ILD
  • Lung transplantation for cystic fibrosis before and after availability of elexacaftor/tezacaftor/ivacaftor
  • Elexacaftor-tezacaftor-ivacaftor and circulating neutrophil counts in CF
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society